PL4167965T3 - Zastosowanie kwasu hialuronowego o wysokiej masie cząsteczkowej jako nośnika do transportu do oczu - Google Patents

Zastosowanie kwasu hialuronowego o wysokiej masie cząsteczkowej jako nośnika do transportu do oczu

Info

Publication number
PL4167965T3
PL4167965T3 PL21748935.0T PL21748935T PL4167965T3 PL 4167965 T3 PL4167965 T3 PL 4167965T3 PL 21748935 T PL21748935 T PL 21748935T PL 4167965 T3 PL4167965 T3 PL 4167965T3
Authority
PL
Poland
Prior art keywords
ocular
molecular weight
high molecular
hyaluronic acid
transporting vehicle
Prior art date
Application number
PL21748935.0T
Other languages
English (en)
Inventor
Wolfgang Georg Konrad Müller-Lierheim
Original Assignee
i.com medical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by i.com medical GmbH filed Critical i.com medical GmbH
Publication of PL4167965T3 publication Critical patent/PL4167965T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21748935.0T 2020-06-21 2021-06-21 Zastosowanie kwasu hialuronowego o wysokiej masie cząsteczkowej jako nośnika do transportu do oczu PL4167965T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063041937P 2020-06-21 2020-06-21
PCT/IB2021/000426 WO2021260430A1 (en) 2020-06-21 2021-06-21 Use of high molecular weight hyaluronic acid as ocular transporting vehicle

Publications (1)

Publication Number Publication Date
PL4167965T3 true PL4167965T3 (pl) 2025-03-24

Family

ID=77155816

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21748935.0T PL4167965T3 (pl) 2020-06-21 2021-06-21 Zastosowanie kwasu hialuronowego o wysokiej masie cząsteczkowej jako nośnika do transportu do oczu

Country Status (9)

Country Link
US (2) US20230338541A1 (pl)
EP (2) EP4167960A1 (pl)
JP (3) JP2023530189A (pl)
KR (1) KR20230041692A (pl)
CN (1) CN115989021A (pl)
BR (1) BR112022025908A2 (pl)
ES (1) ES3008008T3 (pl)
PL (1) PL4167965T3 (pl)
WO (2) WO2021260430A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781175A1 (en) 2018-04-18 2021-02-24 i.com Medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
KR102485499B1 (ko) * 2022-07-15 2023-01-09 오가노이드사이언스 주식회사 신장 질환의 치료 또는 예방용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK10C (da) * 1895-04-08 Carl Salomon Apparat til Tørring og Ristning.
DE3684887D1 (de) * 1985-11-29 1992-05-21 Biomatrix Inc Arzneistoffabgabesysteme auf basis von hyaluronan, dessen derivaten und salzen sowie verfahren zu deren herstellung.
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
SI1759702T1 (sl) * 2004-05-26 2009-06-30 Bayardo Arturo Jimenez Postopek pripravljanja oftalmiäśne raztopine latanoprosta in tako proizvedena raztopina
KR100938233B1 (ko) * 2007-12-04 2010-01-22 주식회사태준제약 프로스타글란딘계 점안용 조성물과 그의 제조 방법
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
DE102009021372A1 (de) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
EP3871682A1 (en) * 2016-10-14 2021-09-01 i.com Medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
EA202092471A1 (ru) * 2018-04-18 2021-03-25 Ай.КОМ МЕДИКАЛ ГМБХ Высокомолекулярная гиалуроновая кислота для улучшения выживания эпителия и восстановления поверхностей тела

Also Published As

Publication number Publication date
EP4167960A1 (en) 2023-04-26
WO2021260427A1 (en) 2021-12-30
EP4167965C0 (en) 2024-12-25
KR20230041692A (ko) 2023-03-24
EP4167965B1 (en) 2024-12-25
CN115989021A (zh) 2023-04-18
WO2021260430A1 (en) 2021-12-30
JP2026035663A (ja) 2026-03-04
ES3008008T3 (en) 2025-03-21
JP7828519B2 (ja) 2026-03-12
JP2023530189A (ja) 2023-07-13
EP4167965A1 (en) 2023-04-26
US20230338541A1 (en) 2023-10-26
JP2023530188A (ja) 2023-07-13
BR112022025908A2 (pt) 2023-03-14
US20230233687A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
PL4167965T3 (pl) Zastosowanie kwasu hialuronowego o wysokiej masie cząsteczkowej jako nośnika do transportu do oczu
BR112013003969A2 (pt) composições de resina recicladas e dispositivos médicos descartáveis produzidos delas
AU2012307812A8 (en) Ophthalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
EA201270134A1 (ru) Пегилированная l-аспарагиназа
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
AU2011288503A8 (en) 6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
PH12020550230A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2010007116A3 (en) Pyridons as pdk1 inhibitors
WO2011112766A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2012008722A3 (ko) 조직 증강용 충전 조성물
MY194002A (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
WO2016057270A3 (en) Titanium phosphinimide and titanium iminoimidazolidide catalyst systems with activator-supports
CA2782122A1 (en) Compositions and methods for stabilized polysaccharide formulations
BR112013014388A2 (pt) suspensão aquosa de um inibidor de encefalinase e processo de preparação de uma suspensão aquosa
RU2017118261A (ru) Содержащая хитозан композиция, стерилизованная путем нагрева, а также способ ее получения
MY180363A (en) Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders
NZ610732A (en) Novel angiotensin type 2 (at2) receptor agonists and uses thereof
CO6612202A2 (es) Inhibidores heterparílicos bicíclicos de pde4
WO2014096951A3 (en) Anti termite cable sheathing comprising an aliphatic polyamide x.y with x+y>18, an uv absorber and/or uv stabilizer, and an antioxidant
WO2013112381A3 (en) New class of anti-adhesion hydrogels with healing aspects
EP3608343C0 (en) PROCESS FOR THE PREPARATION OF LOW MOLECULAR WEIGHT HYALURONIC ACID
GB201114293D0 (en) Endothelial polymers
RU2012111781A (ru) Композиция технологического масла
MX2022013342A (es) Composicion antiviral y antibacteriana.
WO2016148455A3 (ko) 몬테루카스트의 생체이용률을 개선시키기 위한 방법